

# Treating OSA in Diabetes Could Have Big Payoff

BY SUSAN LONDON

SEATTLE — Treating obstructive sleep apnea in patients with type 2 diabetes could improve glycemic control as much as using common antidiabetic drugs, according to the results of an observational study.

The study of 54 patients with type 2 diabetes indicated that blood glucose levels may be harder to control in those with un-

treated OSA, Dr. Renee Simon Aronsohn reported at the annual meeting of the Associated Professional Sleep Societies.

Results showed that mean glycosylated hemoglobin (HbA<sub>1c</sub>) rose significantly from a value of 6.5% in patients without OSA to 8.7% in those with severe OSA, she said. The higher HbA<sub>1c</sub> values also were significantly related to the number of episodes of oxygen desaturation of 3% or more during REM sleep.

In published reports, the prevalence of polysomnography-proven OSA in type 2 diabetes has ranged from 58% to 86%. “Despite this strikingly high prevalence of disease in patients with type 2 diabetes, the impact of OSA on glucose control in this patient population” has remained unknown, said Dr. Aronsohn, an endocrinology fellow at the University of Chicago.

She and her colleagues enrolled 54 pa-

tients seen in outpatient clinics during 2000-2008 who had physician-diagnosed type 2 diabetes and were on stable doses of medication for diabetes and comorbidities. A total of 29 patients (54%) were women, and 29 (54%) were black.

Participants completed a diabetes and quality of life survey, performed wrist actigraphy monitoring for 5 days at home, underwent overnight laboratory polysomnography, and had an HbA<sub>1c</sub> measurement.

On the basis of their apnea-hypopnea index, 76% of the patients had OSA, which was classified as mild in 35% (score of 5-14), moderate in 26% (15-29), and severe in 15% (30 or greater). Compared with their counterparts without OSA, patients with OSA, on average, were older (60 years vs. 53 years), had a higher body mass index (35 vs. 29 kg/m<sup>2</sup>), and had a greater prevalence of

REGISTER NOW

WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

Earn up to  
11 Credits  
of CME


Rheumatology News® • Family Practice News® • Internal Medicine News®

PRESENT A CONTINUING MEDICAL EDUCATION CONFERENCE

PERSPECTIVES IN RHEUMATIC DISEASES 2009™

DECEMBER 4-5, 2009

Loews Santa Monica Beach Hotel  
Santa Monica, California



#### REGISTRATION

—Before 8/1/2009— After 9/15/2009  
Discount Extended to  
9/15/2009

Physicians	\$350	\$450
Physician Assistant	\$250	\$350
Nurse Practitioner	\$250	\$350
Residents	\$250	\$350

#### HOTEL ACCOMMODATIONS

Loews Santa Monica Beach Hotel,  
Santa Monica, California, Phone: (310) 458-6700.  
Mention **Rheumatology Conference** for preferred rates.

#### Daniel E. Furst, MD, CHAIR

Carl M. Pearson Professor of Medicine  
Department of Medicine, Division of Rheumatology  
David Geffen School of Medicine at the  
University of California, Los Angeles (UCLA)

#### Kenneth B. Gordon, MD, CO-CHAIR

Head, Division of Dermatology  
NorthShore University HealthSystem  
Northwestern University Feinberg School of  
Medicine, Chicago

#### PROGRAM HIGHLIGHTS\*

Predicting the Course of RA	Juvenile Idiopathic Arthritis
Co-Morbid Conditions and RA	Psoriasis Update
Vaccine Use in Vulnerable Patients	Psoriatic Arthritis
Gout and Hyperuricemia	Cutaneous Lupus: Better Outcomes
Systemic Scleroderma	Cardiovascular Risk Factors in RA
Rheumatic Diseases and IBD	Fibromyalgia
Steroid-Induced Osteoporosis	Update on Osteoarthritis
Managing Your Practice	Interactive Clinical Cases

#### FACULTY

Roy D. Altman, MD, University of California, Los Angeles  
Clifton O. Bingham, III, MD, Johns Hopkins University  
Chad S. Boomershine, MD, PhD, Vanderbilt University  
John J. Cush, MD, Baylor University Medical Center  
Joseph S. Eastern, MD, UMDNJ & Seton Hall University  
David F. Fiorentino, MD, PhD, Stanford University School of Medicine  
Daniel E. Furst, MD, University of California, Los Angeles  
Kenneth B. Gordon, MD, Northwestern University  
Thomas J.A. Lehman, MD, Cornell University  
Kimberly P. Liang, MD, University of Pittsburgh  
Brian Mandell, MD, PhD, Cleveland Clinic  
Soumya M. Reddy, MD, New York University  
Kenneth G. Saag, MD, MSc, University of Alabama at Birmingham

\*Program subject to change. Go to conference website for updates.

#### TARGET AUDIENCE

This continuing medical education conference is designed for rheumatologists, internists, family practice physicians and healthcare professionals involved in the treatment of patients with rheumatic diseases.

#### LEARNING OBJECTIVES

At the conclusion of this conference, participants will be able to:

- Identify the therapeutic options in the management of rheumatic diseases
- Explain the connection between rheumatic diseases and CV risk
- Recognize the aspects of care, treatment, and overall outcomes that are important to pediatric patients
- Describe the long-term safety and efficacy of systemic and biologic agents in the treatment of psoriasis and psoriatic arthritis
- Evaluate patients to determine their risk for disease progression
- Recognize and describe the clinical manifestations and complications of scleroderma
- Develop a strategy for a diagnostic workup for fibromyalgia
- Discuss the challenges in managing the RA patient with IBD
- Explain the clinical manifestations and risk factors associated with gout

#### ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin Disease Education Foundation (SDEF). The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

#### AMA PRA CREDIT DESIGNATION STATEMENT

The EOCME designates this educational activity for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### AAFP ACCREDITATION

This activity has been reviewed and is acceptable for up to 10.5 Prescribed credit(s) by the American Academy of Family Physicians.

Jointly sponsored by



Treating OSA may improve glucose control as much as widely used pharmacologic agents.

DR. ARONSOHN

diabetic complications (68% vs. 23%). The patients with OSA also had less total sleep time on polysomnography (6.3 hours vs. 7.2 hours), poorer sleep efficiency (81% vs. 90%), and less time spent in REM sleep (20% vs. 27%).

In a multivariate analysis that adjusted for potential confounders (age, sex, race, BMI, insulin use, duration of diabetes, and total sleep time), mean HbA<sub>1c</sub> increased significantly across OSA categories, with values of 6.5%, 7.5%, 7.8%, and 8.7% among patients with no, mild, moderate, and severe OSA, respectively.

“It’s important to note that the magnitude of the effect sizes we see here are comparable to—if not exceeding—those seen with widely used pharmacologic agents,” Dr. Aronsohn commented.

Two other measures of OSA severity were significantly and positively associated with log-transformed HbA<sub>1c</sub> values: the number of obstructive events in REM sleep and the number of oxygen desaturations of 3% or greater during REM sleep.

Giving a clinical example, she noted that a 100% increase in the number of obstructive events during REM sleep, from the median of 35 to 70 events per night, would result in a predicted increase in median HbA<sub>1c</sub> from 7.2% to 7.7%, which is clinically significant, she said.

“Our findings suggest that untreated OSA may worsen glucose control and increase the need for more intensive pharmacotherapy,” Dr. Aronsohn said. “Conversely, treatment of OSA may improve glucose control comparable to that of widely used pharmacologic agents.”

Dr. Aronsohn reported that she had no conflicts of interest associated with the study.

For more information go to  
www.rheumatologynewsperspectives.com or call 973.290.8225